Tirzepatide

Tirzepatide is a dual GIP and GLP-1 receptor agonist used for blood sugar regulation and weight loss. It works by stimulating insulin secretion in a glucose-dependent manner, reducing glucagon levels, decreasing food intake, and slowing gastric emptying, thereby improving insulin sensitivity. It is widely used for type 2 diabetes and chronic weight management in adults with obesity or overweight with weight-related comorbidities.

It has a half-life of approximately 5 days, requiring once-weekly injections. Recommended dosages typically start at 2.5 mg once weekly, increasing to a maintenance dose of 5 mg, 10 mg, or 15 mg per week, with gradual increases over time.